BCT — Briacell Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$26.93m
- CA$19.46m
Annual cashflow statement for Briacell Therapeutics, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2020 July 31st | C2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -3.67 | -13.8 | -26.8 | -20.3 | -4.93 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.066 | 8.33 | 14.7 | 0.074 | -26.3 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.44 | -2.28 | -0.391 | -3.53 | 7.05 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.16 | -7.75 | -12.5 | -23.7 | -24.1 |
| Capital Expenditures | — | — | — | — | -0.457 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | — | — | — | -0.225 |
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | — | — | — | -0.682 |
| Financing Cash Flow Items | — | 0 | -0.057 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.07 | 65 | -3.74 | 3.95 | 4.42 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.124 | 57.2 | -16.2 | -19.8 | -20.4 |